リキッドバイオプシー市場：バイオマーカー、サンプル、タイプ、技術、適応症、エンドユーザー、用途別-2025年～2030年世界予測

リキッドバイオプシー市場の2023年の市場規模は60億米ドルで、2024年には67億2,000万米ドルに達すると予測され、CAGR 12.19％で成長し、2030年には134億4,000万米ドルに達すると予測されています。

リキッドバイオプシーは急成長している診断技術であり、主に血液などの非固形生体組織を分析してがんやその他の疾患を検出します。この技術は、循環腫瘍細胞（CTC）、無細胞DNA（cfDNA）、その他のバイオマーカーを同定し、従来の組織生検に代わる非侵襲的な方法を提供します。リキッドバイオプシーの必要性は、がんの早期発見、腫瘍動態のモニタリング、治療方針の決定、組織生検の限界（アクセスや実行可能性など）を克服する可能性によって強調されます。その用途は腫瘍学、非侵襲的出生前検査（NIPT）、移植モニタリングに及び、最終用途は病院、研究所、学術機関に及ぶ。

主な市場成長要因としては、技術の進歩、がん罹患率の増加、個別化医療に対する意識の高まりなどが挙げられます。最新のビジネスチャンスは、リアルタイムのがんモニタリングとプレシジョン・オンコロジーにおけるアプリケーションの拡大にあり、非侵襲的診断ツールに対する高いアンメットニーズに対応します。企業は、検出感度と特異度を向上させるための調査に投資し、ヘルスケアプロバイダーとパートナーシップを結んで採用を加速させることで、戦略を立てることができます。リキッドバイオプシー市場における課題には、規制上のハードル、高コスト、検査の精度と標準化に関する技術的問題などがあります。また、偽陽性／陰性の可能性も大きな障壁となっています。

複雑なゲノムデータをよりよく解析するためのバイオインフォマティクスツールの強化、より広範なバイオマーカーを捕捉するためのアッセイ技術の改善、ポイントオブケア検査ソリューションの開発など、革新的な分野の開拓が必要です。市場競争は激しく、科学は急速に進歩し、研究開発のための共同作業への傾向が強いのが特徴です。戦略的提携を結び、強固な臨床試験に投資する企業が成功する可能性が高いです。まとめると、リキッドバイオプシーは魅力的な機会を提供するが、その市場成長には、技術的・規制的課題の克服、検査の費用対効果の改善、明確な臨床的有用性の実証が不可欠です。

市場力学：急速に進化するリキッドバイオプシー市場の主要市場インサイトを公開

リキッドバイオプシー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんの罹患率および有病率の上昇
  • 非侵襲的診断方法への嗜好の高まり
• 市場抑制要因
  • 循環腫瘍細胞（CTC）の存在量が少なく、壊れやすい性質
• 市場機会
  • マイクロアレイと次世代シーケンサー（NGS）の大幅な利用
  • リキッドバイオプシー分野のがん研究を拡大するための資金提供の可能性
• 市場の課題
  • 不透明な規制と償還シナリオ

ポーターの5つの力：リキッドバイオプシー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：リキッドバイオプシー市場における外部からの影響の把握

外部マクロ環境要因は、リキッドバイオプシー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析リキッドバイオプシー市場における競合情勢の把握

リキッドバイオプシー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスリキッドバイオプシー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、リキッドバイオプシー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨リキッドバイオプシー市場における成功への道筋を描く

リキッドバイオプシー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの発生率と罹患率の上昇
    • 非侵襲的診断手順に対する好みの増加
  • 抑制要因
    • 循環腫瘍細胞（CTC）の少ない存在と脆弱な性質
  • 機会
    • マイクロアレイと次世代シーケンシング（NGS）の重要な利用
    • リキッドバイオプシー分野におけるがん調査の拡大のための資金提供
  • 課題
    • 不明確な規制と償還シナリオ
• 市場セグメンテーション分析
  • バイオマーカー：遺伝子変化の特定に多用途に使える遊離DNA（cfDNA）の重要な利用
  • サンプル：幅広い臨床応用と強力なデータサポートにより、血液ベースの液体生検の使用が増加しています。
  • タイプ：がん症状の早期発見とスクリーニングのための検査キットの利用の進化
  • テクノロジー：次世代シーケンシング（NGS）を使用した複数遺伝子の並列解析が好まれるようになり、より高いスループットのデータが得られるようになりました。
  • 適応症：乳がんの有病率が高いため、乳がんに対するリキッドバイオプシー検査が急増している
  • エンドユーザー：臨床診断ラボ全体でリキッドバイオプシーテストの使用が急増
  • 応用：早期がんスクリーニングのためのリキッドバイオプシーの指数関数的利用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ
  • メイントラックベースの治療：Mraketの規模と予測2018年～2030年

第6章 リキッドバイオプシー市場：バイオマーカー別

• 遊離DNA
• 循環腫瘍細胞
• 循環腫瘍DNA
• 細胞外小胞

第7章 リキッドバイオプシー市場：サンプル別

• 血液ベース
• 尿ベース

第8章 リキッドバイオプシー市場：タイプ別

• アッセイキット
• 機器
• サービス

第9章 リキッドバイオプシー市場：技術別

• NGSを用いた複数遺伝子並列解析
• PCRマイクロアレイを用いた単一遺伝子解析

第10章 リキッドバイオプシー市場：適応症別

• がんの適応症
  • 乳がん
  • 大腸がん
  • 肺がん
  • 悪性黒色腫
  • 前立腺がん
• 非がん適応症

第11章 リキッドバイオプシー市場：エンドユーザー別

• 学術研究センター
• 臨床診断検査室
• 病院
• 医師のオフィスの検査室

第12章 リキッドバイオプシー市場：用途別

• 早期がん検診
• 再発モニタリング
• 治療法の選択
• 治療モニタリング

第13章 南北アメリカのリキッドバイオプシー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋のリキッドバイオプシー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカのリキッドバイオプシー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • FDA、進行性前立腺がんの標的治療としてFoundationOne Liquid CDxを承認
  • Labcorpは新しいリキッドバイオプシーサービスで精密腫瘍学ポートフォリオを拡大し、がん診断と患者ケアを強化します
  • Personalis Inc.が高度なゲノム技術で診断に革命を起こす商用がんMRD検査を開始
  • ロイヤル・マースデンNHS財団トラストとガーダント・ヘルスが提携し、高度なリキッドバイオプシー検査で肺がんの検出と治療を強化
  • フロリダ州、早期がん治療対応にディアカルタのRadTox検査を採用、州全体の患者ケアを促進
  • GediCubeによるCyclomicsの買収により、リキッドバイオプシーセクターにおけるイノベーションと市場リーチが向上
  • Myriad Genetics、ゲートウェイ・ゲノミクスの戦略的買収によりリキッドバイオプシー市場で拡大
  • Veracyte Inc.がC2i Genomics Ltd.を買収し、AI強化リキッドバイオプシーテクノロジーでがん検出を向上
  • イルミナ社、ゲノムプロファイリングの強化とがんの個別化治療のための先進的なリキッドバイオプシーアッセイを発表
  • UCLA、がんの検出と管理の強化を目指して、リキッドバイオプシー技術の革新に460万米ドルを確保
  • デルフィ・ダイアグノスティクスの革新的な血液検査は肺がんのスクリーニングを強化し、患者の転帰を改善することを目指す
  • Harbinger Health、リキッドバイオプシーテクノロジーでがんの早期発見を推進するためシリーズBで1億4,000万米ドルを調達
• 戦略分析と提言
  • F.ホフマン・ラ・ロシュ株式会社
  • イルミナ株式会社
  • キアゲン
  • ガーダントヘルス株式会社

企業一覧

• ANGLE PLC
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Biocartis NV
• CellMax Life, Inc.
• Danaher Corporation
• DiaCarta, Inc.
• Dxcover Limited
• Epic Sciences Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Laboratory Dr. med. Pachmann
• Lucence Health Inc.
• LungLife AI, Inc.
• MDxHealth SA
• Menarini Silicon Biosystems SpA
• Merck KGaA
• Myriad Genetics, Inc.
• Natera, Inc.
• Neogenomics, Inc.
• OncoDNA SA
• PerkinElmer, Inc.
• Personalis, Inc.
• QIAGEN N.V.
• SAGA Diagnostics AB
• Strand Life Sciences Pvt Ltd.
• Sysmex Corporation
• Tempus AI, Inc.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. LIQUID BIOPSY MARKET RESEARCH PROCESS
• FIGURE 2. LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 23. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 29. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIQUID BIOPSY MARKET DYNAMICS
• TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 68. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 109. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 110. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 117. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 118. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. TAIWAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. THAILAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. VIETNAM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. EGYPT LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. FINLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 244. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. ISRAEL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 254. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 255. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 258. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 259. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. NIGERIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. NORWAY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 285. POLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 286. POLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 287. POLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 288. POLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 289. POLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 290. POLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. POLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 292. POLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 293. QATAR LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 294. QATAR LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 295. QATAR LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 296. QATAR LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 297. QATAR LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 298. QATAR LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 299. QATAR LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 300. QATAR LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 316. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 324. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 332. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 335. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 336. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 337. SWEDEN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 338. SWEDEN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 339. SWEDEN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 340. SWEDEN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 343. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 344. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 345. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 346. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 347. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 348. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 349. TURKEY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 350. TURKEY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 351. TURKEY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 352. TURKEY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 353. TURKEY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 354. TURKEY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 355. TURKEY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 356. TURKEY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 357. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 358. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 359. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 360. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 361. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 362. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 363. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 364. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 365. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 366. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 367. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 368. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 369. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 370. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 371. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 372. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 373. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 374. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023, expected to reach USD 6.72 billion in 2024, and is projected to grow at a CAGR of 12.19%, to USD 13.44 billion by 2030.

Liquid biopsy is a rapidly growing diagnostic technology that involves analyzing non-solid biological tissues, primarily blood, to detect cancer and other conditions. The technique identifies circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers, offering a non-invasive alternative to traditional tissue biopsies. The necessity of liquid biopsy is underscored by its potential for early cancer detection, monitoring tumor dynamics, guiding treatment decisions, and overcoming the limitations of tissue biopsy, such as accessibility and feasibility. Its applications extend to oncology, non-invasive prenatal testing (NIPT), and transplant monitoring, while end-use spans hospitals, research laboratories, and academic institutions.

Key market growth factors include technological advancements, increasing cancer prevalence, and growing awareness of personalized medicine. The latest opportunities lie in expanding applications in real-time cancer monitoring and precision oncology, addressing the high unmet need for non-invasive diagnostic tools. Companies can strategize by investing in research to improve detection sensitivity and specificity, and by forming partnerships with healthcare providers to accelerate adoption. Challenges in the liquid biopsy market include regulatory hurdles, high costs, and technical issues related to the accuracy and standardization of tests. The potential for false positives/negatives also poses a significant barrier.

Innovative areas ripe for exploration include enhancing bioinformatics tools to better analyze complex genomic data, improving assay technologies for broader biomarker capture, and developing point-of-care testing solutions. The liquid biopsy market is characterized by fierce competition, rapid scientific progression, and a strong inclination toward collaborative efforts for research and development. Firms engaging in strategic alliances and investing in robust clinical trials are more likely to succeed. In summary, while liquid biopsy offers compelling opportunities, its market growth is contingent upon overcoming technical and regulatory challenges, improving the cost-effectiveness of tests, and demonstrating clear clinical utility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liquid Biopsy Market

The Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence and prevalence of cancer
  • Increasing preference for noninvasive diagnostic procedures
• Market Restraints
  • Low abundance and fragile nature of the circulating tumor cells (CTCs)
• Market Opportunities
  • Significant use of microarrays and next-generation sequencing (NGS)
  • Availability of funding to expand cancer research in the field of liquid biopsy
• Market Challenges
  • Unclear regulatory and reimbursement scenario

Porter's Five Forces: A Strategic Tool for Navigating the Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liquid Biopsy Market

A detailed market share analysis in the Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liquid Biopsy Market

A strategic analysis of the Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, CellMax Life, Inc., Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.
• Based on Sample, market is studied across Blood Based and Urine Based.
• Based on Type, market is studied across Assay Kits, Instruments, and Services.
• Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.
• Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
• Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.
• Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence and prevalence of cancer
    • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
  • 5.1.2. Restraints
    • 5.1.2.1. Low abundance and fragile nature of the circulating tumor cells (CTCs)
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant use of microarrays and next-generation sequencing (NGS)
    • 5.1.3.2. Availability of funding to expand cancer research in the field of liquid biopsy
  • 5.1.4. Challenges
    • 5.1.4.1. Unclear regulatory and reimbursement scenario
• 5.2. Market Segmentation Analysis
  • 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
  • 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
  • 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
  • 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
  • 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
  • 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
  • 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. Maintrac-based Treatment: Mraket size and forecast 2018-2030 (USD Million)

6. Liquid Biopsy Market, by Biomarkers

• 6.1. Introduction
• 6.2. Cell-free DNA
• 6.3. Circulating Tumor Cells
• 6.4. Circulating Tumor DNA
• 6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

• 7.1. Introduction
• 7.2. Blood Based
• 7.3. Urine Based

8. Liquid Biopsy Market, by Type

• 8.1. Introduction
• 8.2. Assay Kits
• 8.3. Instruments
• 8.4. Services

9. Liquid Biopsy Market, by Technology

• 9.1. Introduction
• 9.2. Multi-gene Parallel Analysis using NGS
• 9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

• 10.1. Introduction
• 10.2. Cancer Indication
  • 10.2.1. Breast Cancer
  • 10.2.2. Colorectal Cancer
  • 10.2.3. Lung Cancer
  • 10.2.4. Melanoma
  • 10.2.5. Prostate Cancer
• 10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

• 11.1. Introduction
• 11.2. Academic & Research Centers
• 11.3. Clinical Diagnostic Laboratories
• 11.4. Hospitals
• 11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

• 12.1. Introduction
• 12.2. Early Cancer Screening
• 12.3. Recurrence Monitoring
• 12.4. Therapy Selection
• 12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Liquid Biopsy Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. FDA Approves FoundationOne Liquid CDx for Targeted Treatment of Advanced Prostate Cancer
  • 16.3.2. Labcorp Expands Precision Oncology Portfolio with New Liquid Biopsy Services, Strengthening Cancer Diagnostics and Patient Care
  • 16.3.3. Personalis Inc. Launches Commercialized Cancer MRD Testing to Revolutionize Diagnostics with Advanced Genomic Technologies
  • 16.3.4. Royal Marsden NHS Foundation Trust and Guardant Health Partner to Enhance Lung Cancer Detection and Treatment with Advanced Liquid Biopsy Tests
  • 16.3.5. Florida Adopts DiaCarta's RadTox Test for Early Cancer Treatment Response, Advancing Statewide Patient Care
  • 16.3.6. GediCube's Acquisition of Cyclomics to Boost Innovation and Market Reach in Liquid Biopsy Sector
  • 16.3.7. Myriad Genetics Expands in Liquid Biopsy Market with Strategic Acquisition of Gateway Genomics
  • 16.3.8. Veracyte Inc. Acquires C2i Genomics Ltd. to Elevate Cancer Detection with AI-Enhanced Liquid Biopsy Technology
  • 16.3.9. Illumina Inc. Unveils Advanced Liquid Biopsy Assay for Enhanced Genomic Profiling and Personalized Cancer Treatment
  • 16.3.10. UCLA Secures USD 4.6 Million to Innovate Liquid Biopsy Technology, Aiming for Enhanced Cancer Detection and Management
  • 16.3.11. Innovative Blood Test by Delfi Diagnostics Aims to Enhance Lung Cancer Screening and Improve Patient Outcomes
  • 16.3.12. Harbinger Health Raises USD 140M in Series B to Advance Early Cancer Detection with Liquid Biopsy Technology
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. F. Hoffmann-La Roche Ltd.
  • 16.4.2. Illumina Inc.
  • 16.4.3. QIAGEN N.V.
  • 16.4.4. Guardant Health, Inc.

Companies Mentioned

• 1. ANGLE PLC
• 2. Bio-Rad Laboratories, Inc.
• 3. Bio-Techne Corporation
• 4. Biocartis NV
• 5. CellMax Life, Inc.
• 6. Danaher Corporation
• 7. DiaCarta, Inc.
• 8. Dxcover Limited
• 9. Epic Sciences Inc.
• 10. Exact Sciences Corporation
• 11. F. Hoffmann-La Roche Ltd.
• 12. Guardant Health, Inc.
• 13. Illumina, Inc.
• 14. Laboratory Corporation of America Holdings
• 15. Laboratory Dr. med. Pachmann
• 16. Lucence Health Inc.
• 17. LungLife AI, Inc.
• 18. MDxHealth SA
• 19. Menarini Silicon Biosystems SpA
• 20. Merck KGaA
• 21. Myriad Genetics, Inc.
• 22. Natera, Inc.
• 23. Neogenomics, Inc.
• 24. OncoDNA SA
• 25. PerkinElmer, Inc.
• 26. Personalis, Inc.
• 27. QIAGEN N.V.
• 28. SAGA Diagnostics AB
• 29. Strand Life Sciences Pvt Ltd.
• 30. Sysmex Corporation
• 31. Tempus AI, Inc.
• 32. Thermo Fisher Scientific Inc.